Taysha Gene Therapies, Inc. Common Stock
Here’s whether Taysha Gene Therapies, Inc. Common Stock (TSHA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.62% over 10 days); strong 1-year return of +444.9%; 3-month momentum positive (+41.0%). Concerns: RSI 85 — overbought, elevated pullback risk. Currently 1.1% off its 52-week high. Score: +5/7.
TSHA is in a confirmed uptrend, trading above both its 50-day ($4.63) and 200-day ($4.16) moving averages. With an RSI of 84.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +444.9% compares to +35.1% for SPY (beat the market by 409.8%).